“Cost-effectiveness profile, organizational implications and patient preferences on the use of exogenous TSH therapy (Thyrogen®) vs. THW in thyroid residue ablation in Italy”, FE, vol. 17, no. 3, Oct. 2016, doi: 10.7175/fe.v17i3.1264.